Table 3.
Radiographic changes from baseline after 2 years of treatment
| MTX (n = 37) | TwHF (n = 34) | MTX + TwHF (n = 38) | P | |
|---|---|---|---|---|
| JE at baseline (range 0–280) | ||||
| mean (SD) | 16.76 (22.56) | 20.83 (29.02) | 14.92 (21.26) | |
| median (IQR) | 7.25 (2.00, 25.00) | 7.00 (2.75, 27.00) | 5.00 (2.75,15.50) | 0.589 |
| JSN at baseline (range 0–168) | ||||
| mean (SD) | 11.92 (15.35) | 13.05 (16.18) | 12.34 (16.06) | |
| median (IQR) | 6.25 (0, 17.50) | 3.00 (0.75, 30.75) | 5.00 (1.25, 21.00) | 0.957 |
| TSS at baseline | ||||
| mean (SD) | 28.68 (35.54) | 33.88 (42.97) | 26.99 (35.81) | |
| median (IQR) | 14.75 (2.75, 42.13) | 15.00 (5.00, 47.00) | 14.5 (5.00, 35.25) | 0.738 |
| Estimated annual radiographic progression at baseline† | ||||
| mean (SD) | 20.96 (78.12) | 13.02 (15.07) | 10.84 (15.90) | |
| median (IQR) | 5.74 (1.88, 10.21) | 6.25 (3.51, 20.17) | 5.61 (2.25, 10.37) | 0.635 |
| mTSS at 2 years | ||||
| mean (SD) | 31.94 (37.54) | 36.57 (44.04) | 30.21 (35.99) | |
| median (IQR) | 15.25 (3.94, 42.00) | 18.00 (5.50, 51.67) | 15.71 (7.41, 38.81) | 0.826 |
| ΔmJE | ||||
| mean (SD) | 1.59 (4.43) | 1.33 (2.03) | 1.44 (3.22) | |
| median (IQR) | 0 (0, 1.21) | 0.75 (0, 2.32) | 0.77 (0, 1.50) | 0.939 |
| ΔmJSN | ||||
| mean (SD) | 1.67 (3.32) | 1.31 (2.41) | 1.78 (3.24) | |
| median (IQR) | 0 ( 0, 1.13) | 0 (0, 1. 52) | 0 (0, 2.19) | 0.781 |
| ΔmTSS | ||||
| mean (SD) | 3.24 (6.95) | 2.70 (3.70) | 3.22 (5.66) | |
| median (IQR) | 0.61 (0,4.18) | 1.00 (0,4.14) | 1.04 (0,3.62) | 0.862 |
| ΔmTSS <0.5 | 17 (45.95%) | 12 (35.29%) | 13 (34.21%) | 0.520 |
| ΔmTSS ≤SDD (5.24) | 31 (83.78%) | 27 (79.41%) | 31 (81.58%) | 0.893 |
| ΔmJE ≤SDD (3.37) | 32 (86.49%) | 31 (91.18%) | 35 (92.11%) | 0.691 |
| ΔmJSN ≤SDD (2.85) | 30 (81.08%) | 27 (79.41%) | 31 (81.58%) | 0.955 |
MTX methotrexate, TwHF Tripterygium wilfordii Hook F, JE joint erosion, JSNjoint space narrowing, TSS total Sharp score, mTSS modified total Sharp score, SSD smallest detectable difference
Data are presented as mean (standard deviation, SD) and median (interquartile range, IQR)
The p values were calculated using analysis of variance for baseline scores, while comparison for estimated progression and scores at year 2 was performed using analysis of covariance with baseline score as a covariate. Comparison of the change in score <0.5 or equal to or less than the smallest detectable difference was conducted using the χ2 test
†Estimated annual radiological progression at baseline was defined as the baseline mTSS score divided by disease duration for each patient